Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 16 Jun 2025 for TG Therapeutics, INC..
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Daniel Hume: trading record in brief
Filings by Daniel Hume span 3 companies, the busiest being TG Therapeutics, Inc., National Holdings Corp and Stemline Therapeutics Inc. Over a trading history stretching from 6 July 2016 to 12 June 2025, the count stands at 20 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 16 June 2025, the filings show a share grant in TG Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Daniel Hume
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
14,718 shares0Common StockSEC:0001437749-25-020541:0
62,459 shares0Common StockSEC:0001437749-25-008284:0
22,250 shares0Common StockSEC:0001437749-24-020850:0
20,000 shares0Common StockSEC:0001104659-23-105400:0
43,732 shares0Common StockSEC:0001104659-22-082022:0
20,000 shares0COMMON STOCKSEC:0001104659-21-084259:0
6 of 6 declarations
